Insights
Clinical research, patient guides, and the latest developments in cancer treatment in China
- News
New Zealand Family Thanks Ruijin Hospital Team After Pancreatic Cancer Surgery in Shanghai
A public thank-you letter from a New Zealand-based family highlights the clinical coordination, post-operative support, and trust-building role of Ruijin Hospital's pancreatic surgery team.
-
Patient GuidesA British Chinese Patient Chose Precision Pancreatic Surgery in Nanjing
A 67-year-old British Chinese patient was diagnosed with main-duct IPMN and underwent precision pancreatic surgery with intraoperative pancreatoscopy in Nanjing.
- Clinical Trials
China's Personalized mRNA Vaccine Trial in Resectable Pancreatic Cancer: Why the Sequence Matters
NCT06156267 pairs a personalized tumor vaccine with adebrelimab and chemotherapy in resectable pancreatic cancer. The key signal is the MSK-like treatment sequence — and China's attempt to localize it.
-
ResearchRGL-270 at ASCO 2026: A KRAS G12V mRNA Vaccine for Pancreatic Cancer
A concise read of the RGL-270 ASCO 2026 abstract and why this KRAS G12V mRNA vaccine approach is worth watching in pancreatic cancer.
-
Patient GuidesPancreatic Cancer Surgery in Shanghai: 3 Powerful Reasons Why Western & Southeast Asian PDAC Patients Are Choosing China
Discover why Shanghai is becoming a top destination for PDAC treatment and pancreatic cancer surgery. Learn about world-leading surgeons, innovative therapies like PAAG, lower costs, and fast access without long waiting times.
-
Clinical TrialsClaudin18.2 Targeted Therapies: A Complete Guide to Drugs and Clinical Trials for Gastric and Pancreatic Cancer (2026)
From CT041 CAR-T to Zolbetuximab — a comprehensive look at all Claudin18.2-targeted drugs in development, clinical trial status, efficacy data, and what international patients should know.
-
Clinical TrialsDaraxonrasib (RMC-6236): A Breakthrough Pan-RAS Inhibitor for Pancreatic Cancer
Phase 1-2 data shows daraxonrasib achieves 35% ORR and 13.1-month OS in heavily pre-treated RAS-mutant pancreatic cancer — 3-4x better response than chemotherapy. Published in NEJM 2026.
-
Clinical TrialsIntraperitoneal Chemotherapy for Pancreatic Cancer Peritoneal Metastasis: CRS+HIPEC, NIPEC, and PIPAC Explained
Three intraperitoneal chemotherapy strategies for pancreatic cancer that has spread to the peritoneum — what they are, survival data, risks, and which patients might benefit.
-
ResearchPancreatic Cancer Immunotherapy: Why It Fails and How China Is Fighting Back (2026)
Immunotherapy for pancreatic cancer faces steep barriers — a 'cold' tumor microenvironment, low mutational burden, and dense stroma. Here's the latest clinical data and emerging strategies from Chinese oncology research.
-
ResearchPancreatic Cancer Peritoneal Metastasis: The Vaccine Landscape in 2026
A comprehensive review of cancer vaccine clinical trials for pancreatic peritoneal metastasis — efficacy data, combination strategies, targeted therapies, and what patients should do today.
-
ResearchPancreatic Cancer Peritoneal Metastasis: The Vaccine Landscape in 2026
A comprehensive review of clinical trials, efficacy data, and what it means for patients with peritoneal metastasis today.
-
Clinical TrialsFirst KRAS G12D Protein Degrader Shows Promise in Pancreatic Cancer — NEJM Phase 1 Data (2026)
Setidegrasib achieves 95.5% KRAS G12D protein degradation in pancreatic cancer. NEJM Phase 1 trial results and what they mean for PDAC patients.
-
Clinical TrialsTumor Treating Fields (TTFields) for Locally Advanced Pancreatic Cancer: A New Clinical Trial in Shanghai
Fudan Zhongshan Hospital is recruiting for a Phase II trial combining TTFields with AG chemotherapy for locally advanced pancreatic cancer — a non-invasive approach now included in NCCN guidelines.
- Research
Two Breakthroughs in Pancreatic Cancer: The Toripalimab-AG and PAAG Regimens — Chinese Innovation in Immunotherapy Combinations
A comprehensive comparison of two pioneering Chinese regimens for advanced pancreatic cancer: the 2021 toripalimab-AG triplet (Prof. Cao Dan) and the 2026 ASCO PAAG quadruplet (Prof. Du Juan) — tracing the evolution of immunotherapy combination strategies.
-
ResearchThe PAAG Regimen: A Chinese Innovation Redefining First-Line Treatment for Advanced Pancreatic Cancer
A quadruplet regimen combining penpulimab, anlotinib, nab-paclitaxel, and gemcitabine extends median PFS to 7.7 months in metastatic pancreatic cancer — a 71% improvement over standard AG chemotherapy.
- Patient Guides
US vs. Shanghai: A Cost Comparison for Pancreatic Cancer Surgery
Why some American patients are choosing Shanghai for pancreatic cancer surgery—and the data behind the decision.
-
NewsAlibaba's DAMO PANDA: First AI Model to Receive FDA 'Breakthrough Device' Status for Pancreatic Cancer Screening
Alibaba DAMO Academy's AI model can detect pancreatic cancer from routine CT scans with 92.9% sensitivity and 99.9% specificity — years before symptoms appear. Now FDA-recognized as a breakthrough medical device.
-
Patient GuidesA Brazilian Doctor Told Him: 'Go to Shanghai — That's Where the Best Surgeons Are'
How a Chinese-Brazilian patient flew 20,000 km from São Paulo to Ruijin Hospital for a robotic Whipple procedure — and why his Brazilian surgeon recommended it.
-
ResearchChina's Global Leadership in Pancreatic Cancer: A 2024-2026 Deep Dive
From heavy ion therapy to robotic surgery to KRAS inhibitors — how China went from follower to leader in pancreatic cancer treatment. A comprehensive report on breakthroughs, survival rates, and next-generation drugs.
-
ResearchPancreatic Cancer Therapeutic Vaccines: Evidence Review of 7 Projects (2026)
Deep evidence grading of 7 pancreatic cancer vaccine projects — Neo-P DC, WT1 DC, PCNAT-01, P01, LK101, XH001, RGL-270. What the data actually shows vs. what's marketing.
-
ResearchFrom Follower to Leader: Ruijin Hospital Achieves 21.2% Five-Year Survival in Pancreatic Cancer
How Ruijin Hospital's Pancreatic Disease Center became a global benchmark — 30,000+ cases treated, 21.2% 5-year survival (vs 9-12% global average), 4,000+ robotic surgeries, and China's first voice in the ESMO Asia-Pacific Consensus.
-
Patient GuidesPancreatic Cancer Surgery in Shanghai: What International Patients Need to Know
A disease-focused guide to hepatobiliary-pancreatic oncology in Shanghai — hospitals, surgeons, techniques, and what the data actually says.
-
Patient GuidesUK Patient Waited 6 Months — Flew to Shanghai, Had Surgery in 2 Weeks
How China's visa-free policy is opening a door for pancreatic cancer patients who can't afford to wait — or to pay.
-
Patient GuidesChina's 30-Day Visa-Free Policy Made Pancreatic Cancer Surgery Abroad Feasible
A realistic breakdown of costs, wait times, and logistics for patients considering hepatobiliary-pancreatic surgery in Shanghai.
-
Clinical TrialsClinical Trials Overview: mRNA Cancer Vaccines and Cell Therapies in China (2025)
A comprehensive guide to active clinical trials in China for mRNA vaccines and immune cell therapies targeting solid tumors — including pancreatic cancer, KRAS-mutant cancers, and more. What international patients need to know.
- No articles found in this category.